The addition of Atto-Tec’s dyes and reagents for sample preparation complements the Leica portfolio of microscopy imaging platforms and advanced AI-based analysis software. “With this acquisition, we are now able to support researchers at every stage of the microscopy imaging workflow,” said Dr Annette Rinck, president of Leica Microsystems.

“This can be a key advantage for reliable results, such as in high-plex 3D experiments in cancer research. Our combined expertise will help researchers to reveal the invisible, enable discovery, and ultimately lead to breakthrough research, accelerating therapy development for improving human health,” Rinck continued.

Dr Jörg Reichwein, CEO of Atto-Tec, added: “I am convinced that by becoming an integral part of Leica Microsystems, we will mobilize the right forces to differentiate the microscopy imaging offering further. Direct access to knowledge of subsequent imaging and analysis steps leads to new approaches in developing assays, kits and dyes optimized for the entire workflow.”

Atto-Tec will continue to provide its high-quality services and renowned ATTO dyes, antibody labeling kits, labeled phospholipids, and other reagents. The company’s products will remain available through the known online store and existing partners.